CSIMarket
 

Protagonist Therapeutics inc   (PTGX)
Other Ticker:  
 

Protagonist Therapeutics Inc 's

Competitiveness


 

PTGX Sales vs. its Competitors Q3 2024



Comparing the current results to its competitors, Protagonist Therapeutics Inc reported Revenue increase in the 3 quarter 2024 by 0 % year on year.
The revenue growth was below Protagonist Therapeutics Inc 's competitors' average revenue growth of 12.55 %, achieved in the same quarter.

List of PTGX Competitors





Revenue Growth Comparisons




Net Income Comparison


Protagonist Therapeutics inc , slower than the average decrease reported by the company's competitors of -51.32 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -51.32 %

<<  PTGX Stock Performance Comparisons



*Market share is calculated based on total revenue.





Publicly Traded Peers of Protagonist Therapeutics inc




Argenx se
Share Performance



+5.32%
30 Days



Argenx se
Profile

Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.

More about Argenx se's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 35,301.442 mill. $ 2,494.910 mill. $ -295.053 mill.


Mirati Therapeutics Inc
Share Performance



-0.14%
30 Days



Mirati Therapeutics Inc
Profile

Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.

More about Mirati Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,815.094 mill. $ 38.191 mill. $ -725.878 mill.


Amgen Inc
Share Performance



-13.14%
30 Days



Amgen Inc
Profile

Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.

More about Amgen Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 150,730.200 mill. $ 32,534.000 mill. $ 4,230.000 mill.


Gilead Sciences Inc
Share Performance



+18.34%
This Quarter



Gilead Sciences Inc
Profile

Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.

More about Gilead Sciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 117,901.080 mill. $ 28,299.000 mill. $ 114.000 mill.


Incyte Corporation
Share Performance



+13.87%
30 Days



Incyte Corporation
Profile

Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.

More about Incyte Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 14,648.682 mill. $ 4,075.860 mill. $ 32.482 mill.


Intercept Pharmaceuticals inc
Share Performance



+82.87%
This Quarter



Intercept Pharmaceuticals inc
Profile

Intercept Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics in the field of chronic liver diseases. Their business model revolves around identifying and targeting specific liver diseases with high unmet medical needs, conducting extensive research and clinical trials to develop effective therapies, and then commercializing these drugs globally to generate sustainable revenue streams. By addressing liver diseases with innovative treatments, Intercept aims to improve patient outcomes and establish a profitable position in the pharmaceutical industry.

More about Intercept Pharmaceuticals inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 794.048 mill. $ 288.248 mill. $ -61.612 mill.


Novartis Ag
Share Performance



+0.70%
Over The Past 5 Days



Novartis Ag
Profile

Novartis AG's business model is centered around the development, manufacturing, and marketing of innovative pharmaceutical products.

More about Novartis Ag's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 217,170.520 mill. $ 46,660.000 mill. $ 14,854.000 mill.


Bristol myers Squibb Company
Share Performance



+13.61%
This Year



Bristol myers Squibb Company
Profile

Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.

More about Bristol myers Squibb Company's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 120,978.900 mill. $ 47,435.000 mill. $ -7,247.000 mill.


Akebia Therapeutics Inc
Share Performance



+61.42%
This Year



Akebia Therapeutics Inc
Profile

Akebia Therapeutics Inc's business model revolves around the development and commercialization of innovative therapies for kidney disease.

More about Akebia Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 431.214 mill. $ 169.757 mill. $ -46.653 mill.


Pulmatrix Inc
Share Performance



+11.92%
Over The Past 5 Days



Pulmatrix Inc
Profile

Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.

More about Pulmatrix Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 22.973 mill. $ 11.684 mill. $ -8.848 mill.


Aadi Bioscience Inc
Share Performance



+32.00%
This Quarter



Aadi Bioscience Inc
Profile

Aadi Bioscience Inc operates on a research and development-based business model, focusing on the discovery and development of innovative treatments for cancer. The company aims to leverage its expertise in molecular and computational biology to identify potential drug candidates and advance them through preclinical and clinical trials. Aadi Bioscience Inc primarily generates revenue through collaborations with pharmaceutical companies and licensing agreements for its drug candidates.

More about Aadi Bioscience Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 62.465 mill. $ 25.070 mill. $ -61.687 mill.


Adagene Inc
Share Performance



+13.27%
This Year



Adagene Inc
Profile

Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.

More about Adagene Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 121.517 mill. $ 18.111 mill. $ -18.946 mill.


Adc Therapeutics Sa
Share Performance



+31.36%
This Year



Adc Therapeutics Sa
Profile

Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.

More about Adc Therapeutics Sa's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 232.711 mill. $ 123.485 mill. $ -367.172 mill.


Affimed N v
Share Performance



-36.22%
One Year



Affimed N v
Profile

Affimed N is a biopharmaceutical company that operates through a partnership-based business model, collaborating with leaders in the healthcare industry and utilizing its proprietary technology platform to develop novel cancer immunotherapies. By leveraging these collaborations and its innovative platform, Affimed N aims to advance the development of effective treatments for cancer.

More about Affimed N v 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 9.268 mill. $ -118.651 mill.


Allakos Inc
Share Performance



-67.36%
This Year



Allakos Inc
Profile

Allakos Inc's business model revolves around developing and commercializing innovative therapeutic antibodies to treat allergic and inflammatory diseases.

More about Allakos Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 79.605 mill. $ - mill. $ -178.745 mill.


Alx Oncology Holdings Inc
Share Performance



+2.05%
30 Days



Alx Oncology Holdings Inc
Profile

Alx Oncology Holdings Inc's business model is centered around the development and commercialization of innovative cancer therapeutics.

More about Alx Oncology Holdings Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 78.514 mill. $ - mill. $ -151.159 mill.


Adlai Nortye Ltd
Share Performance



0.00%
This Year



Adlai Nortye Ltd
Profile



More about Adlai Nortye Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 94.052 mill. $ 5.000 mill. $ -104.871 mill.


Aravive Inc
Share Performance



-68.75%
30 Days



Aravive Inc
Profile

Aravive Inc operates on a business model that focuses on developing and commercializing innovative therapies to treat life-threatening diseases by targeting key signaling pathways.

More about Aravive Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.051 mill. $ 6.995 mill. $ -39.847 mill.


Atossa Therapeutics Inc
Share Performance



-11.03%
30 Days



Atossa Therapeutics Inc
Profile

Atossa Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for breast conditions and oncology.

More about Atossa Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 162.247 mill. $ - mill. $ -25.386 mill.


Astrazeneca Plc
Share Performance



+5.00%
Over The Past 5 Days



Astrazeneca Plc
Profile

AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.

More about Astrazeneca Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 103,654.320 mill. $ 45,811.000 mill. $ 5,961.000 mill.


Biomea Fusion Inc
Share Performance



-30.89%
One Year



Biomea Fusion Inc
Profile

Biomea Fusion Inc operates on a business model focused on the development of precision medicine for cancer treatments. They leverage advanced genomic technologies to identify and understand specific gene fusions that drive cancer growth. By developing targeted therapies, they aim to improve patient outcomes and revolutionize cancer treatment.

More about Biomea Fusion Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 249.561 mill. $ - mill. $ -144.008 mill.


Bolt Biotherapeutics Inc
Share Performance



-7.37%
This Quarter



Bolt Biotherapeutics Inc
Profile

Bolt Biotherapeutics Inc's business model focuses on developing novel immunotherapies for the treatment of cancer.

More about Bolt Biotherapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 24.094 mill. $ 9.779 mill. $ -65.085 mill.


Blueprint Medicines Corporation
Share Performance



-0.47%
This Quarter



Blueprint Medicines Corporation
Profile

The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.

More about Blueprint Medicines Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5,997.744 mill. $ 440.233 mill. $ -128.052 mill.


Checkpoint Therapeutics inc
Share Performance



+80.62%
One Year



Checkpoint Therapeutics inc
Profile

Checkpoint Therapeutics Inc is a biopharmaceutical company that develops and commercializes immune-targeted therapies for the treatment of cancer. The company mainly focuses on acquiring, developing, and commercializing targeted immunotherapy and immuno-oncology products. Through collaborations and strategic partnerships, Checkpoint Therapeutics aims to bring innovative and effective therapies to patients while creating value for shareholders.

More about Checkpoint Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 176.923 mill. $ - mill. $ -46.468 mill.


Cogent Biosciences Inc
Share Performance



-6.55%
This Quarter



Cogent Biosciences Inc
Profile

Cogent Biosciences Inc operates on a biopharmaceutical business model focused on the development and commercialization of precision therapies for patients with genetically driven diseases. The company utilizes its proprietary expertise in discovering, designing, and developing therapies to target specific genetic alterations with the aim of improving patient outcomes and quality of life. By leveraging their scientific knowledge and strategic partnerships, Cogent Biosciences Inc aims to advance precision medicine and address unmet medical needs in the field of genetic diseases.

More about Cogent Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,060.344 mill. $ - mill. $ -242.297 mill.


Cytomx Therapeutics Inc
Share Performance



+17.23%
Over The Past 5 Days



Cytomx Therapeutics Inc
Profile

Cytomx Therapeutics Inc is a biopharmaceutical company that focuses on developing novel antibody-based therapeutics for the treatment of cancer. They utilize proprietary Probody technology to create highly specific and targeted therapies that have the potential to improve treatment outcomes for patients with cancer.

More about Cytomx Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 86.909 mill. $ 126.617 mill. $ 13.830 mill.


Cytodyn inc
Share Performance



+0.95%
Over The Past 5 Days



Cytodyn inc
Profile

Cytodyn Inc is a biotechnology company that focuses on the development and commercialization of innovative treatments for a range of diseases, including cancer and viral infections. The company primarily generates revenue through the licensing and sale of its therapeutics to medical institutions and pharmaceutical companies. Cytodyn's business model revolves around the research and development of novel drugs, conducting clinical trials, and forming strategic partnerships to bring their innovative treatments to market.

More about Cytodyn inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 140.679 mill. $ - mill. $ -19.043 mill.


Day One Biopharmaceuticals Inc
Share Performance



+16.22%
One Year



Day One Biopharmaceuticals Inc
Profile

Day One Biopharmaceuticals Inc operates with a business model focused on developing targeted therapies for patients with rare genetic diseases and cancer. They aim to leverage their expertise in precision medicine and drug discovery to create innovative treatments that address unmet medical needs. Their approach involves identifying genetic mutations and developing therapies tailored specifically to target these mutations and improve patient outcomes.

More about Day One Biopharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,312.537 mill. $ 101.953 mill. $ -117.277 mill.


Deciphera Pharmaceuticals Inc
Share Performance



+0.87%
30 Days



Deciphera Pharmaceuticals Inc
Profile

Deciphera Pharmaceuticals Inc's business model revolves around the research, development, and commercialization of precision medicines for the treatment of cancer and other serious diseases.

More about Deciphera Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,236.262 mill. $ 174.910 mill. $ -190.416 mill.


Effector Therapeutics Inc
Share Performance



0.00%
This Quarter



Effector Therapeutics Inc
Profile

Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.

More about Effector Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.001 mill. $ - mill. $ -34.631 mill.


Essa Pharma inc
Share Performance



-71.94%
This Year



Essa Pharma inc
Profile

Essa Pharma Inc.'s business model revolves around the development of targeted small molecule therapeutics for the treatment of cancer. The company aims to address the unmet medical needs of patients with advanced and metastatic forms of prostate and breast cancer. By leveraging their expertise in clinical development and precision medicine, Essa Pharma aspires to bring innovative and effective treatments to market, ultimately improving patient outcomes.

More about Essa Pharma inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 80.302 mill. $ - mill. $ -27.669 mill.


Erasca Inc
Share Performance



+24.11%
One Year



Erasca Inc
Profile

Erasca Inc is a biotechnology company that focuses on discovering and developing innovative therapies for cancer. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to identify and advance multiple drug candidates simultaneously. By collaborating with academic institutions and biopharmaceutical partners, Erasca aims to accelerate the development of cancer treatments to improve patient outcomes.

More about Erasca Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 785.030 mill. $ - mill. $ -159.119 mill.


Genprex Inc
Share Performance



+59.45%
This Quarter



Genprex Inc
Profile

Genprex Inc's business model focuses on the development and commercialization of gene therapies for the treatment of cancer.

More about Genprex Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.920 mill. $ - mill. $ -22.710 mill.


Gossamer Bio Inc
Share Performance



-27.84%
This Year



Gossamer Bio Inc
Profile

Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.

More about Gossamer Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 158.442 mill. $ 105.322 mill. $ -71.647 mill.


G1 Therapeutics Inc
Share Performance



+0.28%
Over The Past 5 Days



G1 Therapeutics Inc
Profile

G1 Therapeutics Inc is a biopharmaceutical company that operates under a research and development business model. They focus on discovering, developing, and commercializing novel therapies to address unmet needs in cancer treatment, with a strong emphasis on targeting specific cellular processes. Their business model involves conducting preclinical and clinical trials, obtaining regulatory approvals, and collaborating with strategic partners to bring their innovative drugs to market.

More about G1 Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 375.198 mill. $ 58.195 mill. $ -44.770 mill.


Werewolf Therapeutics Inc
Share Performance



+19.51%
Over The Past 5 Days



Werewolf Therapeutics Inc
Profile

Werewolf Therapeutics Inc operates with a business model focused on utilizing innovative technologies to develop therapies targeting cancer using immune cell activation.

More about Werewolf Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 85.661 mill. $ - mill. $ -62.118 mill.


Ideaya Biosciences Inc
Share Performance



-10.76%
30 Days



Ideaya Biosciences Inc
Profile

Ideaya Biosciences Inc operates on a precision medicine approach that combines genomics and synthetic lethality to develop targeted cancer therapies. The company focuses on identifying synthetic lethal interactions in cancer and leveraging these insights to discover and develop drugs that selectively target cancer cells. They collaborate with academic institutions and industry partners to advance their therapeutic pipeline and bring innovative treatments to patients in need.

More about Ideaya Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,308.128 mill. $ - mill. $ -178.120 mill.


I mab
Share Performance



-27.15%
This Quarter



I mab
Profile

The I Mab business model focuses on the development and commercialization of innovative biopharmaceutical products. They specialize in the research and development of novel antibodies and other therapeutic agents to address unmet medical needs. By collaborating with strategic partners and leveraging their expertise in drug discovery and clinical development, I Mab aims to bring transformative treatments to patients globally.

More about I mab's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 181.278 mill. $ 3.893 mill. $ -206.439 mill.


Immunogen inc
Share Performance



+617.93%
One Year



Immunogen inc
Profile

Immunogen Inc is a biotechnology company that focuses on the development of antibody-drug conjugates (ADCs) for the treatment of various types of cancer. Their business model is centered around leveraging their proprietary technology platform to create ADCs that deliver potent cancer-killing agents directly to tumor cells. By partnering with pharmaceutical companies, Immunogen aims to advance their ADC candidates through clinical trials and ultimately bring them to market, aiming to improve the lives of cancer patients.

More about Immunogen inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 8,981.436 mill. $ 287.614 mill. $ -73.522 mill.


Immuneering Corporation
Share Performance



+0.49%
Over The Past 5 Days



Immuneering Corporation
Profile

Immuneering Corp operates on a business model that harnesses the power of big data in the field of biomedicine. Through their proprietary technologies, they analyze vast amounts of biological data to gain insights into disease mechanisms, drug discovery, and patient care. They leverage their expertise to provide pharmaceutical companies and healthcare organizations with actionable information for accelerating the development of new therapeutics and improving clinical outcomes.

More about Immuneering Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 61.176 mill. $ - mill. $ -58.069 mill.


Janux Therapeutics Inc
Share Performance



+335.57%
This Year



Janux Therapeutics Inc
Profile

Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.

More about Janux Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,622.176 mill. $ 13.049 mill. $ -60.536 mill.


Kinnate Biopharma Inc
Share Performance



+2.32%
30 Days



Kinnate Biopharma Inc
Profile

Kinnate Biopharma Inc is a company that focuses on developing targeted therapies for genetically-defined cancers.

More about Kinnate Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 124.801 mill. $ - mill. $ -127.154 mill.


Kura Oncology Inc
Share Performance



-32.43%
Over The Past 5 Days



Kura Oncology Inc
Profile

Kura Oncology Inc is a biotechnology company that focuses on the discovery and development of precision medicines for the treatment of cancer. Their business model revolves around leveraging their expertise in oncology to identify and design small molecule drug candidates that target specific genetic mutations or biomarkers. Through strategic partnerships and collaborations, Kura aims to advance their drug candidates through clinical studies and ultimately commercialize these precision medicines for patients in need.

More about Kura Oncology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 934.713 mill. $ - mill. $ -197.552 mill.


Eli Lilly And Company
Share Performance



+35.06%
This Year



Eli Lilly And Company
Profile

Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.

More about Eli Lilly And Company's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 723,819.000 mill. $ 40,863.300 mill. $ 8,369.900 mill.


Lantern Pharma Inc
Share Performance



-25.26%
One Year



Lantern Pharma Inc
Profile

Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.

More about Lantern Pharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 33.356 mill. $ - mill. $ -17.078 mill.


Macrogenics Inc
Share Performance



-66.60%
This Year



Macrogenics Inc
Profile

Macrogenics Inc is a biopharmaceutical company that focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and autoimmune diseases.

More about Macrogenics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 213.744 mill. $ 141.329 mill. $ -97.617 mill.


Mural Oncology Plc
Share Performance



+15.59%
This Quarter



Mural Oncology Plc
Profile

Mural Oncology Plc's business model focuses on developing and commercializing innovative cancer therapies. They likely collaborate with research institutes and pharmaceutical companies to acquire promising drug candidates and conduct rigorous clinical trials. Their revenue is generated through licensing, partnerships, and potential product sales, helping provide solutions for patients suffering from various forms of cancer.

More about Mural Oncology Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 66.922 mill. $ - mill. $ -250.408 mill.


Nucana Plc
Share Performance



-24.43%
30 Days



Nucana Plc
Profile

Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.

More about Nucana Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 69.341 mill. $ - mill. $ -27.632 mill.


Nektar Therapeutics
Share Performance



+79.89%
This Year



Nektar Therapeutics
Profile

Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.

More about Nektar Therapeutics's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 223.896 mill. $ 93.137 mill. $ -168.301 mill.


Nuvalent Inc
Share Performance



+50.42%
One Year



Nuvalent Inc
Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6,324.858 mill. $ - mill. $ -224.285 mill.


Northwest Biotherapeutics inc
Share Performance



-8.72%
Over The Past 5 Days



Northwest Biotherapeutics inc
Profile

Northwest Biotherapeutics Inc's business model focuses on the development and commercialization of personalized immunotherapy products for the treatment of cancer.

More about Northwest Biotherapeutics inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.315 mill. $ 1.557 mill. $ -75.795 mill.


Nextcure Inc
Share Performance



-4.10%
One Year



Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 32.732 mill. $ - mill. $ -58.518 mill.


Olema Pharmaceuticals Inc
Share Performance



-19.00%
This Quarter



Olema Pharmaceuticals Inc
Profile

Olema Pharmaceuticals Inc.'s business model focuses on the research, development, and commercialization of innovative cancer therapies.

More about Olema Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 556.594 mill. $ - mill. $ -122.679 mill.


Oncosec Medical Incorporated
Share Performance



+26.00%
Over The Past 5 Days



Oncosec Medical Incorporated
Profile

Oncosec Medical Incorporated's business model revolves around developing and commercializing innovative immunotherapies for the treatment of various cancers.

More about Oncosec Medical Incorporated's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.717 mill. $ - mill. $ -29.386 mill.


Oncternal Therapeutics Inc
Share Performance



-47.74%
30 Days



Oncternal Therapeutics Inc
Profile

Oncternal Therapeutics Inc's business model focuses on developing and commercializing novel therapies for the treatment of cancer.

More about Oncternal Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.220 mill. $ 2.161 mill. $ -34.575 mill.


Oric Pharmaceuticals Inc
Share Performance



+32.97%
One Year



Oric Pharmaceuticals Inc
Profile

Oric Pharmaceuticals Inc's business model focuses on the development and commercialization of innovative therapeutics for the treatment of cancer.

More about Oric Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 691.318 mill. $ - mill. $ -119.870 mill.


Panbela Therapeutics Inc
Share Performance



-5.11%
30 Days



Panbela Therapeutics Inc
Profile

Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.

More about Panbela Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.578 mill. $ - mill. $ -27.917 mill.


Pfizer Inc
Share Performance



-13.15%
This Year



Pfizer Inc
Profile

Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.

More about Pfizer Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 147,303.100 mill. $ 60,112.000 mill. $ 4,284.000 mill.


Rain Oncology Inc
Share Performance



-1.63%
Over The Past 5 Days



Rain Oncology Inc
Profile

Rain Therapeutics Inc is a biopharmaceutical company that focuses on discovering and developing precision oncology therapies. Their business model revolves around identifying genetic alterations and biomarkers in cancer patients, and then developing targeted therapies to address these specific alterations. By tailoring treatments to individual patients, they aim to improve outcomes and provide more effective and personalized cancer care.

More about Rain Oncology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 44.015 mill. $ - mill. $ -72.260 mill.


Rapt Therapeutics Inc
Share Performance



-91.90%
One Year



Rapt Therapeutics Inc
Profile

Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.

More about Rapt Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 43.572 mill. $ - mill. $ -107.492 mill.


Regeneron Pharmaceuticals Inc
Share Performance



-18.91%
30 Days



Regeneron Pharmaceuticals Inc
Profile

Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.

More about Regeneron Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 87,502.086 mill. $ 13,847.100 mill. $ 4,654.500 mill.


Repare Therapeutics Inc
Share Performance



-34.65%
One Year



Repare Therapeutics Inc
Profile

Repare Therapeutics Inc is a biotechnology company that specializes in the development of precision oncology drugs. Their business model focuses on leveraging synthetic lethality, a targeted therapy approach, to identify and develop small molecule drugs for the treatment of various forms of cancer. By discovering and advancing novel therapeutics, Repare Therapeutics aims to improve patient outcomes and address unmet medical needs in oncology.

More about Repare Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 133.726 mill. $ - mill. $ -84.048 mill.


Sagimet Biosciences inc
Share Performance



+14.38%
Over The Past 5 Days



Sagimet Biosciences inc
Profile

Sagimet Biosciences Inc is a biopharmaceutical company that operates on a research-based business model focused on developing therapeutic solutions for metabolic diseases. They employ a multidisciplinary approach that combines scientific research, preclinical assessments, and clinical trials to advance their drug candidates. Sagimet Biosciences aims to bring effective treatments to patients by leveraging their expertise in metabolic disease biology and collaborating with key stakeholders in the medical community.

More about Sagimet Biosciences inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 166.181 mill. $ - mill. $ -44.104 mill.


Syndax Pharmaceuticals Inc
Share Performance



-24.52%
This Year



Syndax Pharmaceuticals Inc
Profile

Syndax Pharmaceuticals Inc has a business model centered around developing innovative cancer treatments. They focus on leveraging their expertise in epigenetics and immuno-oncology to create therapies that target specific cancer types. Syndax collaborates with strategic partners and utilizes clinical trials to bring their treatments to market and improve patient outcomes.

More about Syndax Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,409.654 mill. $ 16.000 mill. $ -297.062 mill.


Shattuck Labs Inc
Share Performance



-2.70%
Over The Past 5 Days



Shattuck Labs Inc
Profile

Shattuck Labs Inc operates through a platform-based business model, focusing on the development of biotechnology products and solutions. By utilizing its proprietary technology and expertise, the company aims to create innovative therapies targeting various diseases and disorders, ultimately improving patient outcomes. Shattuck Labs Inc collaborates with strategic partners and stakeholders to advance its pipeline, aiming to commercialize its novel treatments and drive growth in the biotech industry.

More about Shattuck Labs Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 54.900 mill. $ 6.407 mill. $ -84.272 mill.


Spyre Therapeutics Inc
Share Performance



0.00%
One Year



Spyre Therapeutics Inc
Profile



More about Spyre Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,416.253 mill. $ - mill. $ -214.902 mill.


Syros Pharmaceuticals Inc
Share Performance



-90.50%
One Year



Syros Pharmaceuticals Inc
Profile

Syros Pharmaceuticals Inc operates based on a business model focused on developing targeted gene control therapies to treat various diseases. The company aims to leverage its gene control platform to identify and exploit unique gene regulatory networks to discover and develop novel therapeutics.

More about Syros Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9.869 mill. $ - mill. $ -97.815 mill.


Tg Therapeutics Inc
Share Performance



+170.19%
One Year



Tg Therapeutics Inc
Profile

TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for patients with hematological malignancies and autoimmune diseases.

More about Tg Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5,506.075 mill. $ 386.634 mill. $ 113.982 mill.


Theseus Pharmaceuticals Inc
Share Performance



+0.74%
30 Days



Theseus Pharmaceuticals Inc
Profile

Theseus Pharmaceuticals Inc operates on a business model focused on the development and commercialization of pharmaceutical products.

More about Theseus Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 177.837 mill. $ - mill. $ -56.612 mill.


Tyme Technologies Inc.
Share Performance



+26.87%
Over The Past 5 Days



Tyme Technologies Inc.
Profile

Tyme Technologies Inc. is a biotechnology company that operates through the development and commercialization of pharmaceutical products. Their business model focuses on the research, development, and sale of proprietary cancer therapy drug candidates. By leveraging innovative technology and strategic partnerships, Tyme aims to bring novel treatment options to the market, improving patient outcomes and addressing unmet medical needs in the oncology field.

More about Tyme Technologies Inc.'s Market Share

Market Cap. Revenues TTM Net Income TTM
$ 53.505 mill. $ - mill. $ -24.192 mill.


Verastem Inc
Share Performance



+55.17%
This Quarter



Verastem Inc
Profile

Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.

More about Verastem Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 163.045 mill. $ - mill. $ -93.454 mill.


Xencor Inc
Share Performance



+12.39%
This Year



Xencor Inc
Profile

Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb? technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.

More about Xencor Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,619.770 mill. $ 85.164 mill. $ -201.678 mill.


Zai Lab Limited
Share Performance



+44.77%
This Quarter



Zai Lab Limited
Profile

Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.

More about Zai Lab Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 27,045.488 mill. $ 355.748 mill. $ -270.848 mill.


Zentalis Pharmaceuticals Inc
Share Performance



+9.43%
This Quarter



Zentalis Pharmaceuticals Inc
Profile

Zentalis Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of small molecule therapies for the treatment of various types of cancer. Their business model revolves around leveraging their expertise in drug discovery, conducting clinical trials, and ultimately commercializing effective cancer treatments. By leveraging their innovative research and development capabilities, Zentalis aims to address unmet medical needs and improve the lives of cancer patients worldwide.

More about Zentalis Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 247.466 mill. $ - mill. $ -179.334 mill.


Mannkind Corporation
Share Performance



-3.52%
30 Days



Mannkind Corporation
Profile

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.

More about Mannkind Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,873.280 mill. $ 267.200 mill. $ 21.567 mill.


Puma Biotechnology Inc
Share Performance



+18.49%
This Quarter



Puma Biotechnology Inc
Profile

Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.

More about Puma Biotechnology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 154.404 mill. $ 227.507 mill. $ 16.769 mill.


Myovant Sciences Ltd
Share Performance



+0.71%
This Quarter



Myovant Sciences Ltd
Profile

Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.

More about Myovant Sciences Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,613.259 mill. $ 379.112 mill. $ -183.770 mill.


Madrigal Pharmaceuticals Inc
Share Performance



+55.18%
30 Days



Madrigal Pharmaceuticals Inc
Profile

Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.

More about Madrigal Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 7,322.724 mill. $ 76.813 mill. $ -518.670 mill.


Medicinova Inc
Share Performance



+26.06%
This Year



Medicinova Inc
Profile

Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.

More about Medicinova Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 102.016 mill. $ - mill. $ -10.294 mill.


Therapeuticsmd Inc
Share Performance



-10.54%
30 Days



Therapeuticsmd Inc
Profile

TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.

More about Therapeuticsmd Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 16.145 mill. $ 1.249 mill. $ -3.879 mill.


Organon and Co
Share Performance



-3.71%
Over The Past 5 Days



Organon and Co
Profile

Organon and Co's business model revolves around developing and manufacturing pharmaceutical products.

More about Organon and Co 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 4,044.416 mill. $ 6,409.000 mill. $ 1,301.000 mill.


Teva Pharmaceutical Industries Limited
Share Performance



-9.69%
30 Days



Teva Pharmaceutical Industries Limited
Profile

Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.

More about Teva Pharmaceutical Industries Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 18,796.470 mill. $ 16,770.000 mill. $ -1,250.000 mill.


Viatris Inc
Share Performance



-0.38%
Over The Past 5 Days



Viatris Inc
Profile

Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.

More about Viatris Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 15,701.232 mill. $ 15,048.500 mill. $ -883.300 mill.


Sanofi
Share Performance



-3.44%
This Year



Sanofi
Profile

Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.

More about Sanofi's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 60,658.992 mill. $ 52,016.960 mill. $ 6,088.320 mill.


Innovation Pharmaceuticals Inc
Share Performance



0.00%
This Quarter



Innovation Pharmaceuticals Inc
Profile

Innovation Pharmaceuticals Inc operates under a business model focused on pharmaceutical research and development. They strive to innovate and discover novel drug candidates to address unmet medical needs. Through collaborations, partnerships, and internal capabilities, they aim to bring potential therapies through clinical trials and eventually to market.

More about Innovation Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -2.620 mill.


Novan Inc
Share Performance



-46.84%
Over The Past 5 Days



Novan Inc
Profile

Novan Inc is a biotechnology company that operates on a dermatology-focused business model. They develop and commercialize innovative therapies that address unmet medical needs in dermatology by utilizing their proprietary nitric oxide technology platform. Novan Inc primarily focuses on developing topical treatments for a range of skin conditions such as acne, atopic dermatitis, and fungal infections.

More about Novan Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.458 mill. $ 24.920 mill. $ -32.050 mill.


Gt Biopharma Inc
Share Performance



-60.20%
This Year



Gt Biopharma Inc
Profile

Gt Biopharma Inc's business model revolves around developing innovative immunotherapies for the treatment of various cancers. The company focuses on harnessing the power of the immune system to target and eliminate cancer cells through its proprietary technology platform. Gt Biopharma Inc aims to advance its therapies through clinical trials and ultimately commercialize them for the benefit of patients worldwide.

More about Gt Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5.213 mill. $ - mill. $ -11.354 mill.


Tonix Pharmaceuticals Holding Corp
Share Performance



-54.82%
This Year



Tonix Pharmaceuticals Holding Corp
Profile

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.

More about Tonix Pharmaceuticals Holding Corp 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11.729 mill. $ 11.291 mill. $ -139.274 mill.


Allarity Therapeutics Inc
Share Performance



+4.20%
Over The Past 5 Days



Allarity Therapeutics Inc
Profile

Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.

More about Allarity Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.954 mill. $ - mill. $ -19.612 mill.


Biophytis Sa
Share Performance



-25.59%
Over The Past 5 Days



Biophytis Sa
Profile

Biophytis SA is a biotechnology company that focuses on developing innovative therapeutics for age-related diseases, with a specific emphasis on degenerative eye diseases and muscle wasting conditions. They leverage their expertise in biology and clinical development to discover and advance targeted drug candidates, aiming to address the unmet medical needs of patients in these areas.

More about Biophytis Sa's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 131.738 mill. $ - mill. $ -19.069 mill.


Cadrenal Therapeutics Inc
Share Performance



+78.05%
This Quarter



Cadrenal Therapeutics Inc
Profile

Cadrenal Therapeutics Inc's business model revolves around the development and commercialization of innovative therapies in the field of renal diseases.

More about Cadrenal Therapeutics Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 15.136 mill. $ - mill. $ -5.837 mill.


Vaccinex Inc
Share Performance



-0.54%
Over The Past 5 Days



Vaccinex Inc
Profile

Vaccinex Inc operates on a biopharmaceutical business model, focusing on the development and commercialization of antibody-based therapies. The company utilizes its proprietary ActivMAb? Antibody Discovery Technology to discover and develop novel antibody therapeutics for the treatment of various diseases. Vaccinex collaborates with strategic partners and pharmaceutical companies to advance the clinical development and commercialization of its product candidates.

More about Vaccinex Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 7.479 mill. $ - mill. $ -20.172 mill.


Cns Pharmaceuticals Inc
Share Performance



-99.80%
This Year



Cns Pharmaceuticals Inc
Profile

CNS Pharmaceuticals Inc's business model focuses on developing innovative solutions and treatments for central nervous system diseases.

More about Cns Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.582 mill. $ - mill. $ -17.057 mill.


Aclaris Therapeutics Inc
Share Performance



+245.71%
This Year



Aclaris Therapeutics Inc
Profile

Aclaris Therapeutics Inc is a company that focuses on developing and commercializing innovative therapies to address significant unmet needs in dermatology and immunology. Their business model involves researching and developing treatments for various skin and hair conditions, obtaining regulatory approvals, and marketing these therapies to healthcare professionals and patients.

More about Aclaris Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 259.116 mill. $ 27.080 mill. $ -37.004 mill.


Abvc Biopharma Inc
Share Performance



-69.88%
One Year



Abvc Biopharma Inc
Profile

ABVC Biopharma Inc is a pharmaceutical company that focuses on the development and commercialization of innovative biopharmaceutical products.

More about Abvc Biopharma Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6.277 mill. $ 0.524 mill. $ -8.756 mill.


Immuron Limited
Share Performance



-30.60%
This Quarter



Immuron Limited
Profile

Immuron Limited's business model involves the development and commercialization of oral immunotherapeutics that target and treat various diseases.

More about Immuron Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 4.345 mill. $ 1.480 mill. $ -3.787 mill.


Iterum Therapeutics Plc
Share Performance



+75.21%
This Quarter



Iterum Therapeutics Plc
Profile

Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.

More about Iterum Therapeutics Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 41.091 mill. $ - mill. $ -30.554 mill.


Verrica Pharmaceuticals Inc
Share Performance



+25.08%
Over The Past 5 Days



Verrica Pharmaceuticals Inc
Profile

Verrica Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing medical solutions for dermatological conditions. Their business model revolves around identifying unmet needs in the dermatology market, conducting rigorous clinical research to develop novel therapies, and efficiently bringing these treatments to market through strategic partnerships and collaborations. Verrica Pharmaceuticals aims to enhance patient outcomes by addressing specific dermatological conditions with innovative solutions.

More about Verrica Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 51.954 mill. $ - mill. $ -84.991 mill.


Casi Pharmaceuticals inc
Share Performance



-29.47%
30 Days



Casi Pharmaceuticals inc
Profile

Casi Pharmaceuticals Inc. operates under a business model that focuses on the development and commercialization of innovative pharmaceutical products. They likely employ a combination of in-house research and development, partnerships, and licensing agreements to bring their products to market. The company may also engage in strategic marketing and distribution partnerships to ensure the successful commercialization of their therapeutics.

More about Casi Pharmaceuticals inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 55.311 mill. $ 33.879 mill. $ -26.259 mill.


Takeda Pharmaceutical Company Limited
Share Performance



-9.31%
This Quarter



Takeda Pharmaceutical Company Limited
Profile

Takeda Pharmaceutical Company Limited operates under a business model that primarily focuses on research, development, and commercialization of innovative pharmaceutical products. They collaborate with various stakeholders across the healthcare industry, including academia, biotechnology companies, and patient advocacy groups, to drive scientific advancements and understand patient needs. By leveraging their expertise, global presence, and strategic partnerships, Takeda aims to make a positive impact on patients' lives while ensuring long-term growth and sustainability.

More about Takeda Pharmaceutical Company Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 21,240.242 mill. $ 29,166.692 mill. $ 986.394 mill.


Pliant Therapeutics Inc
Share Performance



-5.92%
One Year



Pliant Therapeutics Inc
Profile

Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.

More about Pliant Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 810.151 mill. $ - mill. $ -202.059 mill.


Johnson and Johnson
Share Performance



-2.57%
One Year



Johnson and Johnson
Profile

Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.

More about Johnson and Johnson's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 375,838.920 mill. $ 87,696.000 mill. $ 14,684.000 mill.


Merck and Co Inc
Share Performance



-14.35%
This Quarter



Merck and Co Inc
Profile

Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.

More about Merck and Co Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 256,149.815 mill. $ 63,175.000 mill. $ 12,163.000 mill.




Sources: Protagonist Therapeutics inc and all companies mentioned above in this report


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com